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We present the first Asian case of a 77-year-old man who developed pituitary apoplexy (PA) soon after
gonadotropin-releasing hormone agonist (GnRHa) (leuprorelin) injection to treat prostate cancer. Headache,
ophthalmoplegia, visual field deficit, nausea, and vomiting are the typical characteristics of pituitary apoplexy.
Though the occurrence rate is rare, the consequence of this condition can vary from mild symptoms such as
headache to life-threatening scenarios like conscious change. Magnetic resonance imaging is the best imaging
modality to detect PA and sublabial trans-sphenoid pituitary tumor removal can resolve most of PA symptoms and
is so far the best solution in consensus. We also review 11 previous reported cases receiving GnRHa for androgen
deprivation therapy of prostate cancer, and hope to alert clinicians to use GnRHa with caution.
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Androgen deprivation therapy (ADT) is the mainstream
medical treatment consisting of gonadotropin-releasing
hormone agonist (GnRHa) combined with antiandrogens
to avoid transient flare-up in testosterone levels in
treating advanced prostate cancer (PCa) [1]. Pituitary
apoplexy (PA) is bleeding or impaired blood supply of
the pituitary gland at the base of the brain. This usually
occurs in the presence of a tumor of the pituitary.
Rarely, GRHa might induce PA in those who have insidi-
ous pituitary adenoma coincidentally, although most
cases have not been diagnosed previously. Since Ando
et al. reported the first PA case after GnRHa treatment
in 1995 [2], there have been 10 additional cases pub-
lished in the literature. The most common initial clinical
symptom of PA is a sudden headache, often associated
with a rapidly worsening visual field defect or double
vision caused by compression of nerves surrounding the* Correspondence: juanuro@gmail.com
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reproduction in any medium, provided the orgland. If there is no prompt treatment, consciousness
change or death might occur [2-5]. Sudden onset head-
ache, nausea, vomiting, and ensuing visual impairment
are major characteristics that need to be recognized.
According to previous studies, PA results from sudden
hemorrhage or infarction of pituitary adenoma which
appears in 10% to 20% of the general population without
race predilection [6-8]. Herein, we present the first
Asian male who developed PA after receiving his first
dose of leuprorelin. We also reviewed the previous 11
reported cases. It is hoped this review can shed light on
how to approach patients who have been injected with
GnRHa and consequently suffered from pituitary apoplexy.Case presentation
A 77-year-old with prostate cancer confirmed by
transrectal ultrasound biopsy 6 months previously with
Gleason score of 6 (3 + 3) was admitted. Serum prostate-
specific antigen (PSA) level at detection was 31.21 ng/mL.
Magnetic resonance imaging (MRI) showed prostate
cancer at the right posterior aspect of the peripheral zone
with extra capsular extension and right seminal vesicle
invasion with the clinical stage cT3bN0M0. He suffered
from severe generalized headache followed by vomitingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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subcutaneous injection and anti-androgen therapy at
noon. He was admitted to the Emergency Room (ER) be-
cause of pain at midnight. He had hypertension under
regular medication control, peptic and esophageal ulcer,
and old transient ischemia attack, while radiotherapy was
administered for prostate cancer. He denied the habits of
smoking or drinking. There was no history of migraine, or
any type of headache.
Esophagogastroduodenoscopy (EGD) and brain-computed
tomographic (CT) scan were arranged immediately. The
former revealed lacerations at the E-C junction, and the
latter showed no obvious intracerebral hemorrhage. Other
initial presentations at ER were as follows: GCS was
E4V5M6, blood pressure was 181/91 mmHg, and heart
rate was 75 beats/min. Mallory Weiss laceration was
ligated under EGD, but the cause of persistent headache
was still a puzzle. Ophthalmologic examination manifested
left cranial nerve III palsy, ptosis and eye movement
limitation, and newly onset left-side blurred vision (VOS:
0.2 -2 ). Funduscopy showed cup-to-disc ratio of both eyes
was 0.8/0.8. Both eye visual field defects were shown by
auto perimetry. Neurologic examination revealed normal
muscle tone, muscle power, and intact deep tendon reflex.
Laboratory examination revealed normal serum cortisol,
luteinizing hormone, prolactin, insulin like growth factor-1,
and testosterone levels. However, hyponatremia (Na
123 mmol/L) and high follicle stimulating hormone level
(55.3 mIU/mL; normal range 1–19 mIU/mL) were noted.
Brain MRI revealed an enlarged pituitary gland (1.7 ×
1.8 × 1.3 cm) with low signal intensity lesion on T1W
images and slightly hyper intense on T2W images,
indicating the development of pituitary gland infarction
(Figure 1). Due to disease progression, on the 10th day
after GnRHa injection, the patient underwent sub labial
trans-sphenoid pituitary tumor removal with endoscopy
under microscope. Pathological sections exhibited de-
generative cells with necrotic debris, fibrinoid materials,
and mixed inflammatory cells (Figure 2). Neuron Specific
Enolase stain failed to demonstrate any surviving pituitary
gland cells, confirming the development of PA.Figure 1 The enlarged pituitary gland with maximal size of 1.8 cm is no
gland is non-specific, including hypointense signal on T2-weighted images an
on diffusion-weighted imaging. The most specific finding is non-enhancemenTwo months later, his PSA decreased to 0.46 ng/mL.
Moreover, 4 months after surgery, his visual field, range
of EOM, and visual acuity of both eyes had improved
tremendously, and his C/D ratio had returned to 0.6/0.6.
His recovery to date is almost complete.
Conclusions
The occurrence of PA can be induced by several factors,
such as head trauma, cardiac bypass surgery associated
with fluctuating blood pressure, pregnancy, Sheehan
syndrome, anticoagulation, pituitary function test, or as
in our case, GnRHa used for treating PCa [9]. The causal
relationship of GnRHa and PA is established on time
relationship and consistency association. The presented
case is the first Asian male suffering from PA due to
GnRHa administration, illustrating no race predilection.
All PA cases reviewed except the present case were
confirmed to all have pituitary adenoma before GnRHa
administration. Symptoms struck most patients in 1 day
immediately after first injection of GnRHa, and only two
cases had PA onset later on the 9th and 10th days
following treatment. Guerra has described this phe-
nomenon as a biphasic phase, with the first peak
attacking within 4 h and the second peak delayed even
more than 1 week [10]. The exact mechanism of
GnRHa-induced PA is still unclear. Multiple factors
might contribute to the increased risk of bleeding associ-
ated with GnRHa usage. Intrinsic pituitary vasculature
abnormalities, larger size of adenoma, and elevated
intrasellar pressure can account for increased thickness
and edematous change in capillaries, rapid tumor
growth, and decrease in blood flow resulting in following
ischemic change or bleeding. This does make sense but
cannot explain the expeditious onset time (in a few
minutes to a few hours); much quicker than cellular
growth in the pituitary gland. Guerra et al. assumed that
PA induced by GnRHa goes through two mechanisms:
acute phase and subacute process. Subacute process is
induced by multiple factors mentioned above, and the
acute phase is initiated by releasing ample hormones
from granules in a short time. This would raise theted in MRI examination. The signal characteristic of enlarged pituitary
d intermediate signal on T1-weighted images, with no water restriction
t of the pituitary gland, suggestive of infarction or so-called apoplexy.
Figure 2 Microscopic findings of the sections show degenerative cells with necrotic debris, fibrinoid materials, and mixed inflammatory
cells. The NSE stain only discloses the shadows of dead pituitary gland cells. The morphology is compatible with apophysial status.
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in ischemic change and necrosis in adenoma filled with
abnormal neovascularization. Pathologic findings mani-
festing ischemia and necrosis are only confined within
adenoma, which is compatible with this hypothesis. Unfor-
tunately, this meticulous dual speculation is impractical to
be confirmed by pre- and post-apoplexy brain MRI, which
makes room for further investigation [10].
The principle initial acute symptoms are similar to PA
owing to other causes (Table 1). Most cases manifested
moderate to severe headache, possibly attributed to irri-
tation or stretching of dura mater in the sella supplied
by branches of the trigeminal nerve. Other associated
clinical features such as nausea and vomiting are also
commonly seen and can be extremely severe, resulting
in fatal consequences. The present case exhibited upper
GI bleeding due to E-C junction tearing, which might be
related to severe vomiting. Visual symptoms occur after
headache in every patient, including ptosis, ophthalmo-
plegia, decreased visual acuity, loss of visual field, and
anisocoria, consistent with the imaging finding of extra-
sellar extension.
Moreover, hormonal deficiency is indistinctly detected
from physical examination at the time of onset; however,
several cases presented with hypopituitarism without ad-
equate hormonal supplement [2,8]. Previous studies
showed that hyponatremia occurred in 44% of PA cases,
as well as the present case [11]. Randeva et al. postulated
that hyponatremia might correlate with hypocortisolism,
hypothyroidism, inappropriate secretion of antidiuretic
hormone, or a combination of the above [12].
Most pituitary lesions are detected by MRI instead of
CT scan (Table 1). Only 29% of cases could be accurately
diagnosed by CT scan, whereas the detection rate in-
creases to 57% when combined with MRI. In the present
case, brain CT scan could not detect any brain lesion
while only MRI confirmed pituitary infarction. A previ-
ous study demonstrated MRI is a much more accurate
and sensitive tool to identify pituitary adenoma and PA
than CT (88% and 21%, respectively) [12]. With regard
to MRI, the detection rate can be 100% [12].Prompt and proper intervention is crucial to these PA
patients, especially to those who had consciousness
change or cranial nerve palsy. Six patients underwent
surgery after several days of initial presentation, four cli-
ents received medical treatment at first then changed to
surgery because of poor responses, while the first two
reported cases had conservative medical management
only [2-5,7-10,13]. The outcomes of PA are variable, as
according to the previous reports, one expired due to
cardiac arrest, another suffered from disseminated ma-
lignant melanoma, and one had persistent complications
[4,5,8]. Randeva et al. showed that visual acuity could be
remarkably improved by transsphenoidal surgery. In pa-
tients operated on within 8 days, recovery was complete,
but the rate dropped to only 46% after this cut-out
point. Fortunately, the present case completely recov-
ered though necessarily receiving transsphenoidal sur-
gery after 10 days of PA attack.
Whether to have every prostate cancer patient have a
brain MRI before GnRHa injection is still debatable
[4,7,10,11], and is impractical clinically. Intriguingly, a
patient underwent adenoma excision while continuously
receiving GnRHa injection without the occurrence of PA
[9]. This is compatible with the pathological change
within the pituitary adenoma, and augments the possi-
bility that PA could be induced by GnRHa in case of
pituitary adenoma. The occurrence of PA has been
reported in those receiving Leuprorelin, Leuprolide,
Triptorelin, and Goserelin injections [2-5,8-10,14]. Nearly
every kind of GnRHa has the potential to cause ischemia
or bleeding in the pituitary gland.
GnRH analogue is an effective therapy to control PCa.
Rarely, it might induce PA in those who have insidious
pituitary adenoma coincidentally. Sudden onset head-
ache, nausea, vomiting, and ensuing visual impairment
are major characteristics that need to be recognized.
When a patient presents these entities after GnRH
analogue injection, MRI is the golden tool recommended.
Hormonal survey must be done at admission and
discharge, in spite of vital signs being stable. In case of vis-
ual problems, cranial nerve involvement, or decreased




Drug Time of onset Pathologic finding Symptoms and signs Treatment
2013 77 1st Leuprorelin Hours Degenerative cells Severe H/A, N/V, ptosis Tumor removal (surgery)
Current Taiwan 3.75 mg Necrotic debris Partial ophthalmoplegia
2010 60 1st Leuprolide Hours Necrotic tissue Mild H/A, blurry vision Tumor removal (surgery)
Guerra Hemorrhage; 48 h: ptosis/EOM limitation
Stain: LH(+) 9 days: persistent H/A, ptosis,
complete ophthalmoplegia
2007 60 1st Leuprolide 4 h Pituitary adenoma H/A, N/V, △MS, and VD, ptosis,
mild palsy of CN III.
Medical stabilization
Hands 22.5 mg Stain: LH(+), FSH(−), 2 weeks: H/A↑,diplopia, weakness Tumor removal (surgery)
PRL(−) 3 weeks (untreated): confused,
Left CN III, IV, VI paralysis,
2006 70 1st Leuprolide 10 days Pituitary adenoma VD, diplopia and intracranial
HTN, ptosis
SMA (little effect)
Massoud, 11.25 mg 3 months: tumor
removal (surgery)
2006 61 1st Leuprolide Few hours Pituitary adenoma Severe H/A, N/V, ptosis, diplopia Tumor removal (surgery)
Davis 30 mg 2 days: ptosis, diplopia,
CN III palsy, VD
2006 68 1st Goserelin, 4-6 h Pituitary adenoma Mild H/A, Tumor removal (surgery)
Blaut 3,6 mg 5-7 days: severe H/A, N/V,
△consciousness, diplopia, ptosis,
2003 69 1st Leuprolide Hours Pituitary adenoma H/A, VD, few days later: DI Tumor removal (surgery)
Hernandez Stain: FSH(+)
2001 67 1st Goserelin 4 h Pituitary adenoma H/A, N/V IV hydrocortisone




Stain: LH(+), FSH(+) 6 days: cortisone
replacement
1997 62 1st Leuprorelin Soon after
injection
Stain: LH(+), FSH(+) Sudden intracranial HTN Surgery
Reznik
1996 74 1st Leuprolide 15 min Pituitary adenoma Severe H/A, generalized
weakness, N/V.
Steroid therapy




1995 78 Triptorelin Few mins No biopsy H/A Discontinue of the
GnRH agonist




1995 83 Goserelin 9 days No biopsy H/A, N/V Replacement therapy:
30 mg prednisolone QD
Ando 3.6 mg (CT: suprasellar mass) 9-13 days: △ consciousness,
hyponatremia, diplopia,
CN, cranial nerve; CT, computed tomography; EOM, extraocular muscle; FSH, follicle-stimulating hormone; H/A, headache; HTN, hypertension; LH, luteinizing
hormone; MRI, magnetic resonance imaging; N/A, not available; N/V, nausea/vomiting; PRL, prolactin; RD, retinal detachment; RT, radiotherapy; SAH, subarachnoid
hemorrhage; SMA, somatostatin-like analog; VD, visual disturbances; △, change.
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sphenoidal surgery as early as possible. Hormonal replace-
ment might be prescribed for transient or lifelong use.
Consent
A written informed consent was obtained from the pa-
tient for publication of this case report and any accom-
panying images.
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